StreetInsider.com News Articles

Bayer gains on agreement to resolve additional PCB cases

Mon, 18 Aug 2025 10:37:55 -0500

Investing.com -- Bayer shares rose more than 3% on Monday after the company announced an agreement in principle to settle additional cases tied to polychlorinated biphenyls (PCBs).

The deal involves “over 200 plaintiffs” at the Sky Valley Education Center and marks “a step in reducing its PCB litigation exposure,” according to analysts at Jefferies.

While financial terms were not disclosed, the analysts noted that “the settlements are fully covered by the €530 million PCB-related provision recorded in Q2 2025, which also accounts for the Burke case and other related costs.”

The agreement comes after a series of courtroom setbacks. Jefferies highlighted

Bayer gains on agreement to resolve additional PCB cases

Mon, 18 Aug 2025 10:37:55 -0500

Investing.com -- Bayer shares rose more than 3% on Monday after the company announced an agreement in principle to settle additional cases tied to polychlorinated biphenyls (PCBs).

The deal involves “over 200 plaintiffs” at the Sky Valley Education Center and marks “a step in reducing its PCB litigation exposure,” according to analysts at Jefferies.

The agreement comes after a series of courtroom setbacks. Jefferies highlighted

Bayer gains on agreement to resolve additional PCB cases

Mon, 18 Aug 2025 10:37:55 -0500

Investing.com -- Bayer shares rose more than 3% on Monday after the company announced an agreement in principle to settle additional cases tied to polychlorinated biphenyls (PCBs).

The deal involves “over 200 plaintiffs” at the Sky Valley Education Center and marks “a step in reducing its PCB litigation exposure,” according to analysts at Jefferies.

The agreement comes after a series of courtroom setbacks. Jefferies highlighted

Bayer AG (BAYGN) announces FDA approval for Jivi

Mon, 19 May 2025 11:29:39 -0500

Bayer (XETRA: BAYGN)(OTC: BAYRY) announced that the U.S. Food and Drug Administration (FDA) has approved Jivi®, a recombinant DNA-derived, extended half-life factor VIII concentrate, for use in pediatric patients 7 years of age and older with hemophilia A (congenital Factor VIII deficiency).

The approval is based on data from the Alfa-PROTECT and PROTECT Kids studies, demonstrating Jivi’s safety and efficacy in children aged 7 to under 12 years with severe hemophilia A. This significant milestone reflects Bayer’s ongoing commitment to providing effective treatment options for the hemophilia community.

Jivi was first granted approval by the FDA in August 2018 for use in

Bayer AG (BAYGN) announces FDA approval for Jivi

Mon, 19 May 2025 11:29:39 -0500

Jivi was first granted approval by the FDA in August 2018 for use in

Bayer AG (BAYGN) announces FDA approval for Jivi

Mon, 19 May 2025 11:29:39 -0500

Jivi was first granted approval by the FDA in August 2018 for use in

Bayer AG (BAYGN) announces FDA approval for Jivi

Mon, 19 May 2025 11:29:39 -0500

Jivi was first granted approval by the FDA in August 2018 for use in

BofA upgrades Bayer on favorable litigation outlook

Fri, 06 Sep 2024 06:00:43 -0500

Investing.com -- BofA Securities in a note dated Friday upgraded Bayer's (ETR:BAYGN) rating to 'neutral' from 'underperform' reflecting a more favorable outlook on the company’s litigation challenges and overall business prospects.

This upgrade is accompanied by an increase in the price objective to EUR 31 per share (ADR $8.55), up from EUR 21 (ADR $7.60). This is driven by a reassessment of Bayer's litigation provisions and an optimistic outlook for the resolution of key legal battles concerning glyphosate and PCB.